Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2018, Cilt: 9 Sayı: 2, 71 - 75, 13.06.2018
https://doi.org/10.5799/jcei.433807

Öz

Kaynakça

  • 1. Koc C. Nazal Polip, otolaryngology, head and neck surgery. (Ed. Koc C), Ankara, Güneş bookstore 2004; 609–24.
  • 2. Keles B, Cora T, Acar H, et al. Evaluation of HLA-A,-B,-Cw, and-DRB1 alleles frequency in Turkish patients with nasal polyposis. Otolaryngol Head Neck Surg. 2008;139:580-5.
  • 3. Kim KS, Won HR, Park CY, et al. Analyzing serum eosinophil cationic protein in the clinical assessment of chronic rhinosinusitis. Am J Rhinol Allergy. 2013;27: e75–80.
  • 4. Settipane GA, Lund VJ, Tos M. Nasal polyps: epidemiology, pathogenesis and treatment. Oceanside Publications Inc. Providence, Rhode Island, 1997.
  • 5. Okoye IS, Wilson MS. CD4+ T helper 2 cells–microbial triggers, differentiation requirements and effector functions. Immunology. 2011; 134:368-77.
  • 6. Zygmunt B, Veldhoen M. 5 T Helper Cell Differentiation: More than Just Cytokines. Advances in immunology. 2011; 109:159.
  • 7. Cheng W, Zheng C, Tian J, Shi G. T helper cell population and eosinophilia in nasal polyps. J Investig Allergol Clin Immunol. 2007; 17:297-301.
  • 8. Grundmann T, Töpfner M. Treatment of ASS-Associated Polyposis (ASSAP) with a cysteinyl leukotriene receptor antagonist-a prospective drug study on its antiinflammatory effects. Laryngorhinootologie. 2001; 80:576-82.
  • 9. Wierenga EA, Snoek M, Jansen HM, Bos JD, Van Lier RA, Kapsenberg ML. Human atopen-specific types 1 and 2 T helper cell clones. J. Immunol. 1991; 147: 2942–9.
  • 10. Kramer MF, Rasp G. Nasal polyposis: eosinophils and Interleukin-5. Allergy. 1999;55: 669-80.
  • 11. Perić A, Vojvodić D, Radulović V, Vukomanović-Đurđević B, Perić AV, Miljanović O. Proinflammatory cytokine levels in nasal fl uid as indicators of severity of nasal polyposis. Acta Clin Croat. 2010;49:395- 403.
  • 12. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5’flanking sequence. Immunogenetics. 1997;46:120-8.
  • 13. Agnello D, Lankford CS, Bream J, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003;23:147-61.
  • 14. Witowski J, Ksia˛zek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci. 2004;61:567–79.
  • 15. Gaffen, S.L, J.M. Kramer, J.J. Yu, and F. Shen. The IL-17 cytokine family. Vitamins and Hormones 2006;74: 255–82.
  • 16. Zhao A, Wang H, Wu H, Yang Y, Xu H, Wang D. Quantitative analysis of interleukin-5 mRNA and protein in nasal polyps. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;28:1053-6.
  • 17. Kubota K, Takeno S, Taruya T, Sasaki A, Ishino T, Hirakawa K. IL-5 and IL-6 are increased in the frontal recess of eosinophilic chronic rhinosinusitis patients. J Otolaryngol Head Neck Surg. 2017;46:36.
  • 18. Bachert C, Gevaert P, Holtappels G, Cuvelier C, Van Cauwenberge P. Nasal polyposis: from cytokines to growth. Am J Rhinol. 2000; 14:279- 90.
  • 19. Sun DI, Joo YH, Auo HJ, Kang JM. Clinical significance of eosinophilic cationic protein levels in nasal secretions of patients with nasal polyposis. Eur Arch Otorhinolaryngol. 2009;266:981-6.
  • 20. Allen JS, Eisma R, Leonard G, Kreutzer D. Interleukin-3, ınterleukin-5, and granulocyte-macrophage colony-stimulating factor expression in nasal polyps. Am J Otolaryngol. 1997;18:239-46.
  • 21. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the ınterleukin-10 receptor. Annu Rev Immunol. 2001;19:683-7.
  • 22. Domdey A, Liu A, Millner A, et al. The T cellresponse to major grass allergens is regu-lated and includes IL-10 production in ato-pic but not in non-atopic subjects. Int Arch Allergy Immunol. 2010;152:243–54.
  • 23. Ozkara S, Keles E, Ilhan N, Gungor H, Kaygusuz I, Alpay HC. The relationship between Th1/Th2 balance and 1α,25-dihydroxyvitamin D₃ in patients with nasal polyposis. Eur Arch Otorhinolaryngol. 2012;269(12):2519-24.
  • 24. Molet SM, Hamid QA, Hamilos DL. IL-11 and IL-17 Expression in Nasal Polyps: Relationship to Collagen Deposition and Suppression by Intranasal Fluticasone Propionate. Laryngoscope 2003;113:1803-12.
  • 25. Jiang XD, Li GY, Li L, Dong Z, Zhu DD. The characterization of IL-17A expression in patients with chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2011;25:171-5.
  • 26. Dellacono FR, Eisma R, Lafreniere D, Leonard G, Kreutzer D. Interferon Gamma Expression in Human Nasal Polyps. Laryngoscope. 1997;107:626-30.

Levels of Th1 and Th2 Cytokines in Patients with Nasal Polyps

Yıl 2018, Cilt: 9 Sayı: 2, 71 - 75, 13.06.2018
https://doi.org/10.5799/jcei.433807

Öz

Objective: We aimed to investigate Th1 / Th2 (T helper) cell balance by examining Interleukin-4
(IL-4), Interleukin-5 (IL-5), Interleukin-10 (IL-10), Interleukin-17 (IL-17) and Interferon gamma
(IFN γ) levels in serum in patients with nasal polyps (NPs).
Patients and Methods: This study included 45 patients (mean age: 34.8 years) with NPs and a
control group (mean age: 37.9) consisting of 45 healthy volunteers.
Results: The mean IL-17 level in the NPs group (4.096 pg/ml) was significantly higher than the
control group (2.219 pg/ml) (p<0.001). IL-5 levels were significantly higher in the control group.
NPs group had significantly lower IL-5 level compared with the control group (1.981 pg/ml vs.
2.720 pg/ml, respectively: p<0.001).
The mean IFN γ concentration was significantly lower in the NPs group (0.379 pg/ml) compared
to the control group (0.439 pg/ml) (p=0.011). No significant differences were found in the IL-4
(3.25 pg/ml vs. 3.38 pg/ml) and IL-10 (11.249 pg/ml vs. 12.156 pg/ml) concentrations between
NPs and the control groups (p=0.799 and p=0.255, respectively).
Conclusions: Increased IL-17 levels were found in NPs patients. There was no significant
differences in IL-4 and IL-10 values of the Th1 cytokines among the groups, whereas IL-5 was
found to be low in the NPs group. IFN gamma values of Th2 cytokines were found to be low in
the NPs group. According to these results, low IFN gamma levels and regulatory cytokine IL-7
activation may be effective in the etiopathogenesis of NPs.

Kaynakça

  • 1. Koc C. Nazal Polip, otolaryngology, head and neck surgery. (Ed. Koc C), Ankara, Güneş bookstore 2004; 609–24.
  • 2. Keles B, Cora T, Acar H, et al. Evaluation of HLA-A,-B,-Cw, and-DRB1 alleles frequency in Turkish patients with nasal polyposis. Otolaryngol Head Neck Surg. 2008;139:580-5.
  • 3. Kim KS, Won HR, Park CY, et al. Analyzing serum eosinophil cationic protein in the clinical assessment of chronic rhinosinusitis. Am J Rhinol Allergy. 2013;27: e75–80.
  • 4. Settipane GA, Lund VJ, Tos M. Nasal polyps: epidemiology, pathogenesis and treatment. Oceanside Publications Inc. Providence, Rhode Island, 1997.
  • 5. Okoye IS, Wilson MS. CD4+ T helper 2 cells–microbial triggers, differentiation requirements and effector functions. Immunology. 2011; 134:368-77.
  • 6. Zygmunt B, Veldhoen M. 5 T Helper Cell Differentiation: More than Just Cytokines. Advances in immunology. 2011; 109:159.
  • 7. Cheng W, Zheng C, Tian J, Shi G. T helper cell population and eosinophilia in nasal polyps. J Investig Allergol Clin Immunol. 2007; 17:297-301.
  • 8. Grundmann T, Töpfner M. Treatment of ASS-Associated Polyposis (ASSAP) with a cysteinyl leukotriene receptor antagonist-a prospective drug study on its antiinflammatory effects. Laryngorhinootologie. 2001; 80:576-82.
  • 9. Wierenga EA, Snoek M, Jansen HM, Bos JD, Van Lier RA, Kapsenberg ML. Human atopen-specific types 1 and 2 T helper cell clones. J. Immunol. 1991; 147: 2942–9.
  • 10. Kramer MF, Rasp G. Nasal polyposis: eosinophils and Interleukin-5. Allergy. 1999;55: 669-80.
  • 11. Perić A, Vojvodić D, Radulović V, Vukomanović-Đurđević B, Perić AV, Miljanović O. Proinflammatory cytokine levels in nasal fl uid as indicators of severity of nasal polyposis. Acta Clin Croat. 2010;49:395- 403.
  • 12. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5’flanking sequence. Immunogenetics. 1997;46:120-8.
  • 13. Agnello D, Lankford CS, Bream J, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003;23:147-61.
  • 14. Witowski J, Ksia˛zek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci. 2004;61:567–79.
  • 15. Gaffen, S.L, J.M. Kramer, J.J. Yu, and F. Shen. The IL-17 cytokine family. Vitamins and Hormones 2006;74: 255–82.
  • 16. Zhao A, Wang H, Wu H, Yang Y, Xu H, Wang D. Quantitative analysis of interleukin-5 mRNA and protein in nasal polyps. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;28:1053-6.
  • 17. Kubota K, Takeno S, Taruya T, Sasaki A, Ishino T, Hirakawa K. IL-5 and IL-6 are increased in the frontal recess of eosinophilic chronic rhinosinusitis patients. J Otolaryngol Head Neck Surg. 2017;46:36.
  • 18. Bachert C, Gevaert P, Holtappels G, Cuvelier C, Van Cauwenberge P. Nasal polyposis: from cytokines to growth. Am J Rhinol. 2000; 14:279- 90.
  • 19. Sun DI, Joo YH, Auo HJ, Kang JM. Clinical significance of eosinophilic cationic protein levels in nasal secretions of patients with nasal polyposis. Eur Arch Otorhinolaryngol. 2009;266:981-6.
  • 20. Allen JS, Eisma R, Leonard G, Kreutzer D. Interleukin-3, ınterleukin-5, and granulocyte-macrophage colony-stimulating factor expression in nasal polyps. Am J Otolaryngol. 1997;18:239-46.
  • 21. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the ınterleukin-10 receptor. Annu Rev Immunol. 2001;19:683-7.
  • 22. Domdey A, Liu A, Millner A, et al. The T cellresponse to major grass allergens is regu-lated and includes IL-10 production in ato-pic but not in non-atopic subjects. Int Arch Allergy Immunol. 2010;152:243–54.
  • 23. Ozkara S, Keles E, Ilhan N, Gungor H, Kaygusuz I, Alpay HC. The relationship between Th1/Th2 balance and 1α,25-dihydroxyvitamin D₃ in patients with nasal polyposis. Eur Arch Otorhinolaryngol. 2012;269(12):2519-24.
  • 24. Molet SM, Hamid QA, Hamilos DL. IL-11 and IL-17 Expression in Nasal Polyps: Relationship to Collagen Deposition and Suppression by Intranasal Fluticasone Propionate. Laryngoscope 2003;113:1803-12.
  • 25. Jiang XD, Li GY, Li L, Dong Z, Zhu DD. The characterization of IL-17A expression in patients with chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2011;25:171-5.
  • 26. Dellacono FR, Eisma R, Lafreniere D, Leonard G, Kreutzer D. Interferon Gamma Expression in Human Nasal Polyps. Laryngoscope. 1997;107:626-30.
Toplam 26 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Araştırma Yazısı
Yazarlar

Adnan Ekinci

Muge Ozcan Bu kişi benim

Yayımlanma Tarihi 13 Haziran 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 9 Sayı: 2

Kaynak Göster

APA Ekinci, A., & Ozcan, M. (2018). Levels of Th1 and Th2 Cytokines in Patients with Nasal Polyps. Journal of Clinical and Experimental Investigations, 9(2), 71-75. https://doi.org/10.5799/jcei.433807
AMA Ekinci A, Ozcan M. Levels of Th1 and Th2 Cytokines in Patients with Nasal Polyps. J Clin Exp Invest. Haziran 2018;9(2):71-75. doi:10.5799/jcei.433807
Chicago Ekinci, Adnan, ve Muge Ozcan. “Levels of Th1 and Th2 Cytokines in Patients With Nasal Polyps”. Journal of Clinical and Experimental Investigations 9, sy. 2 (Haziran 2018): 71-75. https://doi.org/10.5799/jcei.433807.
EndNote Ekinci A, Ozcan M (01 Haziran 2018) Levels of Th1 and Th2 Cytokines in Patients with Nasal Polyps. Journal of Clinical and Experimental Investigations 9 2 71–75.
IEEE A. Ekinci ve M. Ozcan, “Levels of Th1 and Th2 Cytokines in Patients with Nasal Polyps”, J Clin Exp Invest, c. 9, sy. 2, ss. 71–75, 2018, doi: 10.5799/jcei.433807.
ISNAD Ekinci, Adnan - Ozcan, Muge. “Levels of Th1 and Th2 Cytokines in Patients With Nasal Polyps”. Journal of Clinical and Experimental Investigations 9/2 (Haziran 2018), 71-75. https://doi.org/10.5799/jcei.433807.
JAMA Ekinci A, Ozcan M. Levels of Th1 and Th2 Cytokines in Patients with Nasal Polyps. J Clin Exp Invest. 2018;9:71–75.
MLA Ekinci, Adnan ve Muge Ozcan. “Levels of Th1 and Th2 Cytokines in Patients With Nasal Polyps”. Journal of Clinical and Experimental Investigations, c. 9, sy. 2, 2018, ss. 71-75, doi:10.5799/jcei.433807.
Vancouver Ekinci A, Ozcan M. Levels of Th1 and Th2 Cytokines in Patients with Nasal Polyps. J Clin Exp Invest. 2018;9(2):71-5.